EUVIMEDEUVIMED entdecken
Crossref

Do we need to use neoadjuvant carboplatin in all patients with triple-negative breast cancer?

Piotr J. Wysocki

Oncology in Clinical Practice · 15.01.2026 · 22

DOI: 10.5603/ocp.109345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology in Clinical Practice, online erschienen am 15.01.2026. Verfasst von Piotr J. Wysocki.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Wysocki, P. J. (2026). Do we need to use neoadjuvant carboplatin in all patients with triple-negative breast cancer?. Oncology in Clinical Practice, 22(0). https://doi.org/10.5603/ocp.109345

Vancouver

Wysocki PJ. Do we need to use neoadjuvant carboplatin in all patients with triple-negative breast cancer?. Oncology in Clinical Practice. 2026;22(0). doi:10.5603/ocp.109345

BibTeX
@article{Wysocki2026,
  author = {Wysocki, Piotr J.},
  title = {Do we need to use neoadjuvant carboplatin in all patients with triple-negative breast cancer?},
  journal = {Oncology in Clinical Practice},
  year = {2026},
  volume = {22},
  number = {0},
  doi = {10.5603/ocp.109345}
}
Kostenlos starten →